SOUTH SAN FRANCISCO --December 9, 2017 --AmphivenaTherapeutics Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell redirector for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), will present today in an oral presentation at the 59thAnnual Meeting of the...
SOUTH SAN FRANCISCO – November 29, 2017 – Amphivena Therapeutics Inc., a privately held biotechnology company developing a novel CD33/CD3 T cell engager for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), announced today that it has received Orphan Drug Designation from...
SOUTH SAN FRANCISCO -- September 11, 2017 -- Amphivena Therapeutics, Inc., a privately held biotechnology company developing a novel CD33/CD3-bispecific T cell engaging antibody for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), is pleased to announce three additions to the company’s...